Alpha-Klotho in Parkinson’s Disease: A Perspective On Experimental Evidence And Potential Clinical Implications
Jul 14, 2023
α-Klotho protein (KL) has been discovered more than 20 years ago and immediately emerged as a master regulator of aging-related processes, which operates as an anti-aging factor. It is expressed through the entire human body, representing the choroid plexus and the kidney as the most active sources at the central nervous system (CNS) and periphery level respectively. To a lesser extent, also the parathyroid gland, the adipose tissue, and the liver express KL.
Glycoside of cistanche can also increase the activity of SOD in heart and liver tissues, and significantly reduce the content of lipofuscin and MDA in each tissue, effectively scavenging various reactive oxygen radicals (OH-, H₂O₂, etc.) and protecting against DNA damage caused by OH-radicals. Cistanche phenylethanoid glycosides have a strong scavenging ability of free radicals, a higher reducing ability than vitamin C, improve the activity of SOD in sperm suspension, reduce the content of MDA, and have a certain protective effect on sperm membrane function. Cistanche polysaccharides can enhance the activity of SOD and GSH-Px in erythrocytes and lung tissues of experimentally senescent mice caused by D-galactose, as well as reduce the content of MDA and collagen in lung and plasma, and increase the content of elastin, have a good scavenging effect on DPPH, prolong the time of hypoxia in senescent mice, improve the activity of SOD in serum, and delay the physiological degeneration of lung in experimentally senescent mice With cellular morphological degeneration, experiments have shown that Cistanche has the good antioxidant ability and has the potential to be a drug to prevent and treat skin aging diseases. At the same time, echinacoside in Cistanche has a significant ability to scavenge DPPH free radicals and has the ability to scavenge reactive oxygen species and prevent free radical-induced collagen degradation, and also has a good repair effect on thymine free radical anion damage.
Click on Where Can I Buy Cistanche
【For more info:george.deng@wecistanche.com / WhatApp:86 13632399501】
KL is a transmembrane protein serving as an essential co-receptor for fibroblast growth factor receptors, but, in general, it mediates several molecular pathways and biological functions at a multisystem level. Even a soluble form exists, originated by the extracellular domain cleavage, which circulates in human fluids, allowing a sort of systemic signaling. Although all the tissue-specific actions have not been completely clarified, there is solid evidence that KL regulates basic mineral homeostasis and internal metabolism pathways. In the CNS, instead, it accounts for wide structural and neuroprotective effects (Cheikhi et al., 2019).
Experimental down-regulation of KL in models causes a premature aging phenotype, including neurodegenerative features, visceral and musculoskeletal involvement, and shorter lifespan. Conversely, the overexpression leads to improved cognition and neuroprotective anti-aging effects; as well, the protein administration prevents and limits damage progression in different models of acute/chronic internal diseases (kidney and heart injuries) via antioxidant and anti-inflammatory mechanisms (Cheikhi et al., 2019).
Several studies linked the higher circulating KL levels to better health outcomes, lower risk for chronic disorders, and longer life expectancy in humans. Contrariwise, the reduction has been associated either with cardiovascular diseases and macrovascular events in patients with type 2 diabetes, or chronic kidney failure complications. Moreover, in many internal, age-related disorders, peripheral KL levels have been correlated with the severity of clinical course and prognosis. Accordingly, KL has gained weight as a theoretical biomarker of age-related tissue dysfunction, but also in the context of potential therapies counteracting age-related decline (Cheikhi et al., 2019).
Neurodegenerative diseases, namely Alzheimer’s disease (AD) and Parkinson’s disease (PD) as the two most common forms, dominate the scene of age-related disorders. As expected, the KL pathway is involved even in these conditions. There is evidence that KL is reduced in the brain of AD patients and mouse models; as well, different correlations between KL activity and clinical phenotype or amyloid-β and tau burden have been discovered (Belloy et al., 2020). Regarding PD, instead, the first data are just arriving, but they were immediately impressed by the potential clinical implications.
In this perspective, therefore, we will summarize the current evidence on the role of KL in PD, referring to main preclinical and clinical studies; then, we will anticipate the possible next advancements to make KL either a useful biomarker or a candidate therapeutic target for PD.
Involvement of KL pathway in PD and potential clinical implications: PD is a neurodegenerative disorder whose pathological hallmarks are the loss of dopaminergic cells from the substantia nigra pars compacta and the intraneuronal accumulation of α-synuclein positive Lewy bodies. Patients with PD suffer from a progressive, disabling, and heterogeneous syndrome, including the cardinal motor signs (bradykinesia, rigidity, tremor, postural and gait disturbances) and a wide spectrum of non-motor symptoms. Available therapies for PD are based on dopamine replacement, providing only symptomatic relief. Effective disease-modifying treatments, indeed, still lack, as well as reliable disease biomarkers supporting diagnosis, prognostic evaluation, and progression monitoring. The discovery of biomarkers and the development of novel therapies both depend on a deeper comprehension of the pathogenic mechanisms of PD. Specifically, there is a need to identify molecules, whose quantitative assessment in peripheral tissues and fluids may inform on the underlying pathological events, but that could also serve as targets for intervention counteracting neurodegeneration and disease progression (Sancesario et al., 2021). In the last decade, studies from preclinical m o d e l s a n d h u m an n p at I e nt s o n t h e involvement of KL in PD supported the research in this field, highlighting a clinical potential for KL pathway in the PD field.
Experiments on animal models demonstrated the neuroprotective properties of KL in PD, mostly operated via the mitigation of Piergiorgio Grillo, Michele Basilicata, Tommaso Schirinzi* neuropathological changes, the halting of main pathogenic drivers (oxidative stress and neuroinflammation), and the modulation of synaptic plasticity (Cheikhi et al., 2019). Specifically, Kosakai et al. (2011) found that KL-deficient mice, compared to wildtype littermates, had a significant reduction of mesencephalic dopaminergic neurons from both substantia nigra pars compact and ventral tegmental area, together with lower levels of striatal dopamine. On the other hand, the acute intraperitoneal injection of KL in a PD mouse model expressing transgenic α-synuclein leads to improved cognitive and motor behavior, and enhanced synaptic plasticity in the hippocampus (Leon et al., 2017). As well, the intracerebroventricular injection of KL in the 6-hydroxydopamine lesioned rat model ameliorated motor deficits and tempered down neuropathology, allowing a lower burden of α-synuclein, malondialdehyde, reactive oxygen species, and glial fibrillary acid protein accumulation, together with milder neurodegenerative features (Baluchnejadmojarad et al., 2017).
Recently, clinical data have been also obtained and the shape of KL expression outlined in biofluids of PD patients. Sancesario et al. (2021) provided a paired measurement of KL in cerebrospinal fluid (CSF) and serum of a PD cohort, finding opposite levels in the two compartments. Namely, KL levels were higher than sex/ age-matched healthy controls in CSF, and lower in the blood. No correlations resulted between the two pools or with blood-brain barrier dysfunction, disclosing a distinct KL expression at the central and peripheral levels, which underlies different pathophysiological mechanisms. In fact, in the CSF, levels of KL and those of total α-synuclein were inversely associated, suggesting that increased expression of KL in the CNS may be a defensive response to the deposition of Lewy bodies. Reduction in the blood, instead, has been considered a consequence of systemic inflammation and oxidative stress, two PDrelated phenomena that can suppress the peripheral expression of KL, as described in other chronic-degenerative diseases. Findings from Sancesario et al. (2021) came from a PD cohort at early disease stages (age 59 ± 11 years, disease duration 3.5 ± 3.9 years), when, in theory, defensive responses may be more effective, as the CSF increase of KL in association with accumulating synucleinopathy indicates.
In a larger and more clinically-advanced PD cohort, instead, Zimmermann et al. (2021) found that the CSF KL levels were reduced compared to healthy controls and decreased in parallel with the worsening of motor disturbances. As well, in a group of patients older than those in Sancesario’s cohort, KL plasma levels, measured by an immunoprecipitation-immunoblotting assay, were similar to healthy controls (Kakar et al., 2021). Despite the limitations due to various assay techniques and different study sample sizes, the potential value of KL as a biomarker for PD emerged.
In fact, in the CNS, KL expression seems to change depending on the disease stage or clinical features overall. In early phases, we may see a compensatory increase, which probably serves to counteract growing neurodegeneration (Sancesario et al., 2021). Consistently, PD patients with KL-VS haplotype, which have a lesser functioning KL protein, develop an aggressive phenotype, with more severe motor impairment and earlier cognitive decline (Zimmermann et al., 2021). Along with PD progression, compensatory mechanisms fail, and both neurodegeneration and neuroinflammation spread (Sancesario et al., 2021), with subsequent inhibition of CNS KL expression and a parallel decline of clinical conditions. CSF KL levels may thus inform on the potentiality of neuroprotective systems of the brain, which is critical to stratify patients, especially at the beginning of the disease, and, eventually, to tailor treatments. In the periphery, instead, KL is mostly produced by the kidney and a reduction of circulating levels has been measured in patients with kidney disorders, diabetes, and chronic-degenerative diseases, often with high predictive value in clinical terms (Sancesario et al., 2021). Similarly, in PD, the blood KL levels may serve as a systemic readout of critical pathogenic processes, such as oxidative stress and inflammation, which could be extremely useful to better characterize the individual biological profile of each patient (Figure 1).
More recently it has raised the hypothesis that, in some cases, PD pathology may start from the enteric or the peripheral autonomic nervous system, and successively ascend to CNS mostly via the vagus nerve (“body-first hypothesis”) (Horsager et al., 2020). Gut inflammation has a major role in PD pathogenesis or progression, and may even precede the overt phases of the disease (Brudek, 2019). Of interest, systemic levels of KL decrease in the presence of intestinal inflammation and bowel inflammatory diseases (Thurston et al., 2010), thus supporting the idea that circulating KL reflects events occurring out from the CNS but linked to PD mechanisms. The enteric cells, especially in the colon, also express KL. The abnormal intestinal expression of KL has been then associated with local diseases; namely, a recent study showed that colorectal cancer cells present lower KL levels compared to normal tissue. Conversely, KL overexpression or external administration inhibits cancer proliferation (Arbel Rubinstein et al., 2019).
These data laid the foundations for a direct assessment of KL in the gastrointestinal tract of PD patients for clinical purposes. Besides the direct detection of KL in the enteric mucosa, gastrointestinal KL might be better evaluated in more easily accessible sites, such as the mouth. KL is expressed by the oral mucosa and salivary glands (Tai et al., 2019), which already represent useful sources of fluid biomarkers in PD (Bougea et al., 2019). Likewise, the modulation of KL levels in the gut rises as a novel, hypothetic, disease-modifying treatment for PD, targeting one of the earliest sites of neuropathology.
Conclusions: In conclusion, we have initial evidence that the expression of KL could dynamically reflect either at a central or systemic level the critical molecular mechanisms underlying the various phases of PD. Measurement of KL in different tissues (CSF, blood, other peripheral tissues) might thus inform on the burden of pathogenic forces and the presence of some compensatory attempts, which is fundamental to identify the ideal time-window for successful therapeutic I nte r ve nt I o n s. M o re o ve r, t h e re a re encouraging data indicating KL as a valuable candidate target for novel therapies in the PD field.
Piergiorgio Grillo, Michele Basilicata, Tommaso Schirinzi*
Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, Rome, Italy (Grillo P, Schirinzi T) Department of Experimental Medicine and Surgery, University of Roma Tor Vergata, Rome, Italy (Basilicata M)
*Correspondence to: Tommaso Schirinzi, MD, Ph.D., t.schirinzi@yahoo.com or tommaso.schirinzi@uniroma2.it.
Date of submission: October 29, 2021
Date of decision: December 7, 2021
Date of acceptance: December 21, 2021
Date of web publication: April 29, 2022
Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons AttributionNonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Open peer reviewers: Katarzyna Kuter, Maj Institute of Pharmacology, Polish Academy of Sciences, Poland; Melinda Barkhuizen, Philip Morris International Management SA, Netherlands.
References
Arbel Rubinstein T, Shahmoon S, Zigmond E, Etan T, Merenbakh-Lamin K, Pasmanik-Chor M, Har-Zahav G, Barshack I, Vainer GW, Skalka N, Rosin-Arbesfeld R, Varol C, Rubinek T, Wolf I (2019) Klotho suppresses colorectal cancer through modulation of the unfolded protein response. Oncogene 38:794-807.
Baluchnejadmojarad T, Eftekhari SM, Jamali-Raeufy N, Haghani S, Zeinali H, Roghani M (2017) The antiaging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson’s disease: Involvement of PKA/ CaMKII/CREB signaling. Exp Gerontol 100:70-76.
Belloy ME, Napolioni V, Han SS, Le Guen Y, Greicius MD, Alzheimer’s Disease Neuroimaging I (2020) Association of Klotho-VS heterozygosity with risk of Alzheimer disease in individuals who carry APOE4. JAMA Neurol 77:849-862.
Bougea A, Koros C, Stefanis L (2019) Salivary alpha-synuclein as a biomarker for Parkinson’s disease: a systematic review. J Neural Transm (Vienna) 126:1373- 1382.
Brudek T (2019) Inflammatory bowel diseases and Parkinson’s disease. J Parkinsons Dis 9:S331-S344.
Cheikhi A, Barchowsky A, Sahu A, Shinde SN, Pius A, Clemens ZJ, Li H, Kennedy CA, Hoeck JD, Franti M, Ambrosio F (2019) Klotho: an elephant in aging research. J Gerontol A Biol Sci Med Sci 74:1031-1042.
Horsager J, Andersen KB, Knudsen K, Skjærbæk C, Fedorova TD, Okkels N, Schaeffer E, Bonkat SK, Geday J, Otto M, Sommerauer M, Danielsen EH, Bech E, Kraft J, Munk OL, Hansen SD, Pavese N, Göder R, Brooks DJ, Berg D, et al. (2020) Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain 143:3077-3088.
Kakar RS, Pastor JV, Moe OW, Ambrosio F, Castaldi D, Sanders LH (2021) Peripheral Klotho and Parkinson’s disease. Mov Disord 36:1274-1276.
Kosakai A, Ito D, Nihei Y, Yamashita S, Okada Y, Takahashi K, Suzuki N (2011) Degeneration of mesencephalic dopaminergic neurons in klotho mouse related to vitamin D exposure. Brain Res 1382:109-117.
Leon J, Moreno AJ, Garay BI, Chalkley RJ, Burlingame AL, Wang D, Dubal DB (2017) Peripheral elevation of a Klotho fragment enhances brain function and resilience in young, aging, and alpha-synuclein transgenic mice. Cell Rep 20:1360-1371.
Sancesario GM, Di Lazzaro G, Grillo P, Biticchi B, Giannella E, Alwardat M, Pieri M, Bernardini S, Mercuri NB, Pisani A, Schirinzi T (2021) Biofluids profile of alpha-Klotho in patients with Parkinson’s disease. Parkinsonism Relat Disord 90:62-64.
Tai NC, Kim SA, Ahn SG (2019) Soluble klotho regulates the function of salivary glands by activating KLF4 pathways. Aging (Albany NY) 11:8254-8269.
Thurston RD, Larmonier CB, Majewski PM, Ramalingam R, Midura-Kiela M, Laubitz D, Vandewalle A, Besselsen DG, Muhlbauer M, Jobin C, Kiela PR, Ghishan FK (2010) Tumor necrosis factor and interferon-gamma downregulate Klotho in mice with colitis. Gastroenterology 138:1384-1394.
Zimmermann M, Kohler L, Kovarova M, Lerche S, Schulte C, Wurster I, Machetanz G, Deuschle C, Hauser AK, Gasser T, Berg D, Schleicher E, Metzler W, Brockmann K (2021) The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson s disease. Eur J Neurol 28:1557-1565.
【For more info:george.deng@wecistanche.com / WhatApp:86 13632399501】
